At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,408 enrolled
Drug / intervention
venlafaxinedrug
Likely dose
venlafaxine 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DRUG USE INVESTIGATION OF EFFEXOR(REGISTERED) SR CAPSULES
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Nov 8, 2016·Updated May 22, 2023
In Brief
An observational study evaluating venlafaxine for Depression/Depressed State. Completed, enrolled 1,408 participants.
Detailed Summary
SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDepression/Depressed State
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedNov 2016
Primary CompletionMay 2020
TodayJul 2026
First PostedNov 8, 2016
Enrollment StartOct 3, 2016
Primary CompletionMay 11, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.7 years ago
Interventions
venlafaxinedrug
The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.